Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter Phase 3 Trial Comparing Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma - NADINA

NCT04949113 is registered in ClinicalTrials.gov with The Netherlands Cancer Institute as lead sponsor.

NCT NCT04949113
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04949113 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter Phase 3 Trial Comparing Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma - NADINA
Lead sponsor
The Netherlands Cancer Institute
Phase
Phase 3
Overall status
Active, not recruiting
Start date
July 8, 2021
Completion date
December 19, 2028
Enrollment
423 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

malignant melanoma stage iii